Experts recommend increased visibility for regulatory analysis of primary clinical trial data
Regulatory NewsJeff Craven
Biologics/ biosimilars/ vaccinesMedical DevicesPharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)